Drug Profile
Henagliflozin - Jiangsu HengRui Medicine
Alternative Names: Henggliflozin Tablets - Jinagsu Hengrui Meidicine; Proline Henggliflozin Tablets - Jiangsu HengRui Medicine; Ruiqin; SHR-3824Latest Information Update: 04 May 2022
Price :
$50
*
At a glance
- Originator Jiangsu Hengrui Medicine Co.
- Class Antihyperglycaemics; Chlorobenzenes; Ethers; Fluorobenzenes; Glucosides; Small molecules
- Mechanism of Action Sodium-glucose transporter 2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Type 2 diabetes mellitus
Most Recent Events
- 04 May 2022 Jiangsu Hengrui Medicine completes a phase III trial in Type-2 diabetes mellitus (Combination therapy) in China (Jiangsu Hengrui Medicine Co. pipeline, May 2022)
- 04 May 2022 Jiangsu Hengrui Medicine completes a phase III trial in Type-2 diabetes mellitus (Monotherapy) in China (Jiangsu Hengrui Medicine Co. pipeline, May 2022)
- 31 Dec 2021 Launched for Type 2 diabetes mellitus (Monotherapy) in China (PO) in December 2021